IASO // Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With ALS

Phase 1b pilot trial, prospective, single arm, open-label study

Topic / Pathology

  • SLA
  • Phase 1b pilot trial

Objectives

The purpose of this pilot study is to assess the safety and tolerability of multiple doses of MaaT033 in ALS patients and to analyze the gut microbiota composition and evolution before considering a larger randomized controlled efficacy study.

Find out more : https://classic.clinicaltrials.gov/ct2/show/NCT05889572

 

Sponsor

Maat Pharma

Investigator

National coordinator : Pr Gaëlle Bruneteau

Status

Completed

Participating centers

Share

Updated on 19 December 2024